表紙
市場調查報告書
商品編碼
571062

CD抗原為基礎的癌症治療藥市場:未來展望、臨床實驗趨勢分析

CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023

出版日期: | 出版商: KuicK Research | 英文 500 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供以CD抗原為為基礎的癌症治療藥、診斷藥的市場趨勢的分析,CD抗原的特性和癌症治療、診斷的效果,現在開發中、臨床實驗中的開發中產品的概要,主要的推動及阻礙市場的要素,整體市場規模趨勢預測,各類別的市場規模、價格趨勢預測,今後的市場機會等調查。

第1章 CD抗原系癌症治療藥的概要

第2章 CD抗原的重要性:正常細胞 vs. 癌症細胞

  • 正常細胞內部的CD抗原
  • 癌症細胞內部的CD抗原

第3章 CD抗原系癌症治療藥的功能機制

第4章 CD抗原系實用的癌症治療藥

  • 單株抗體
  • 抗體藥物複合體 (ADC)
  • 雙特異性抗體

第5章 CD抗原系癌症治療藥:近幾年的實用化的動向

  • CAR-T細胞療法
  • 核酸適體
  • 免疫複合體
    • 放射性免疫複合體
    • 毒素免疫複合體
  • 最新型的CD抗原為基礎的抗體
    • BiTE (Bispecific T-Cell Engager) 抗體
    • DART及TandAb

第6章 癌症治療的目標的主要CD抗原

  • CD20
  • CD19
  • CD137
  • CD38
  • CD70
  • CD22
  • CD30
  • CD33
  • CD37

第7章 癌症診斷的目標的主要CD抗原

  • CD20
  • CD5
  • CD56
  • CD66e
  • CD15
  • CD30
  • CD3

第8章 癌症研究主要的CD抗原

  • CD34
  • CD10
  • CD26
  • CD117
  • CD44
  • CD57

第9章 全球CD抗原系癌症治療藥市場概要

  • 市場趨勢
  • 目前市場方案
  • 全球CD抗原系癌症治療藥市場趨勢
  • 全球癌症CD抗原抑制劑市場:開發平台的概要

第10章 主要CD抗原系癌症治療藥:價格、劑量分析

  • Rituximab (CD20)
  • Ofatumumab (CD20)
  • Obinutuzumab (CD20)
  • Daratumumab (CD38)
  • Brentuximab Vedotin (CD30)
  • Gemtuzumab Ozogamicin (CD33)
  • Inotuzumab Ozogamicin (CD22)
  • Ibritumomab Tiuxetan (CD20)
  • Blinatumomab (CD19, CD3)
  • Tisagenlecleucel (CD19)

第11章 已上市的癌症CD抗原抑制劑:臨床、專利分析

  • Rituximab (MabThera,Rituxan)
  • Obinutuzumab (Gazyva,Gazyvaro)
  • Ibritumomab Tiuxetan (Zevalin,Zevamab)
  • Rituximab的生物相似藥 (AcellBia,USMAL)
  • Rituximab的生物相似藥 (Reditux,Tidecron)
  • Rituximab的生物相似藥 (Blitzima,Ritemvia,Truxima,Tuxella)
  • Rituximab的生物相似藥 (Novex)
  • Rituximab的生物相似藥 (RituxiRel,Toritz,Toritz RA)
  • Rituximab的生物相似藥 (Maball)
  • Rituximab的生物相似藥 (Kikuzubam)
  • Rituximab的生物相似藥 (Mabtas)
  • alemtuzumab (Campath,Lemtrada,MabCampath,MabKampat,Remniq)
  • Avelumab (BAVENCIO)
  • Pembrolizumab (Keytruda)
  • Atezolizumab (TECENTRIQ)
  • Durvalumab (Imfinzi)
  • Rituximab的生物相似藥 (Zytux)

第12章 全球CD抗原癌症治療藥市場動態

  • 市場成長促進因素
  • CD抗原市場課題

第13章 全球CD抗原癌症治療藥市場:未來預測

第14章 癌症CD抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 研究
  • 前臨床
  • 第一階段

第15章 癌症CD3抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 前臨床
  • 第一階段
  • 第二階段

第16章 癌症CD4抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 第一階段

第17章 癌症CD7抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 前臨床

第18章 癌症CD19抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第三階段

第19章 癌症CD20抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 不清楚
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第三階段
  • 登記完畢

第20章 癌症CD22抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 前臨床
  • 第三階段
  • 登記完畢

第21章 癌症CD26抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 前臨床
  • 第一/二階段

第22章 癌症CD27抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 研究
  • 前臨床
  • 第二階段

第23章 癌症CD30抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 第一階段

第24章 癌症CD33抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 第一階段
  • 第一/二階段

第25章 癌症CD38抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 研究
  • 前臨床
  • 第一/二階段
  • 第三階段

第26章 癌症CD44抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 前臨床
  • 第一階段

第27章 癌症CD45抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 第三階段

第28章 癌症CD46抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 研究

第29章 癌症CD47抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 研究
  • 前臨床
  • 第一階段
  • 第一/二階段

第30章 癌症CD52抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 研究
  • 前臨床

第31章 癌症CD55抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 前臨床
  • 第二階段

第32章 癌症CD56抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 第二階段

第33章 癌症CD66抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 第一階段

第34章 癌症CD70抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 第二階段

第35章 癌症CD71抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 前臨床

第36章 癌症CD98抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 第一階段

第37章 癌症CD200抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 前臨床
  • 臨床
  • 第二階段

第38章 癌症CD223抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 前臨床
  • 第一階段
  • 第一/二階段
  • 第二階段

第39章 癌症CD248抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 前臨床
  • 第二階段

第40章 癌症CD274抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段

第41章 癌症CD319抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 第一階段

第42章 癌症多重抗原抑制劑的臨床實驗平台:各企業、各症狀、各相位

  • 前臨床
  • 第一階段
  • 第一/二階段

第43章 競爭環境

目錄

“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report gives comprehensive insight into multiple clinical and non-clinical issues related to emergence and development of global CD Antigen cancer therapy market. CD Antigens have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. CD antigens have been present in disguise since the efforts began to develop therapeutic monoclonal antibodies in 1970s. CD antigens are the basis on which monoclonal antibodies were discovered. Although the potential of antibodies was well understood but it required a series of discoveries to find out that specific antibodies are capable of targeting one unique molecular site of the cancer cells.

“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report highlights:

  • Market Opportunity Assessment: More than US$ 60 Billion by 2023
  • Clinical & Patent Insight on 17 Commercialize CD Antigen Drugs
  • Clinical & Licensing Insight on 184 CD Antigens in Clinical Pipeline
  • Dosage & Price Analysis on Key Drugs
  • Mechanism of CD Antigen Cancer Therapeutics
  • Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs
  • Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

CD antigens have been used as targets in a wide variety of cancer therapeutics including monoclonal antibodies, antibody-drug-conjugates, tri-functional and bi-specific T-cell engager antibodies, radio immunoconjugates and CAR T-cell therapies. The current scenario clearly indicates that CD Antigens have acquired a major share in the modern cancer therapy market. Approval and commercialization of such a wide variety of cancer therapeutics have shown that continuous efforts have been made to produce unique and improved anti-cancer products.

Global CD antigen based cancer therapy market has evolved since the approval of first CD antigen targeting monoclonal antibody. Current market is fledged with a variety of CD antigen targeting cancer therapies. The market has successfully produced unique CD antigen based cancer therapies. Clinical trials of these therapies have provided evidences that they are better than the existing conventional cancer therapies and provide better quality adjusted life years and prolonged survival to cancer patients.

Although current global CD antigen based cancer therapeutic market is dominated for treating hematological malignancies but strong clinical pipeline having over 100 CD antigen directing cancer drugs consists of various drugs which will be used for treating solid tumors like breast cancer, lung cancer, colorectal cancer, prostate cancer etc. As the number of patients suffering from solid tumors is much higher than the patients suffering from hematological malignancies; an exponential growth can be experienced by Global CD Antigen Cancer Therapy Market after the approval of anti-CD antigenic cancer drugs for treating solid tumors.

The future CD antigen based cancer therapy market is going to be highly competitive as the pharmaceutical companies have to ensure that they are producing unique and more advanced products. Furthermore, CD antigens based cancer therapies has the potential to become popular amongst the patients and physicians as they provide better survival and have justified their high prices in case of some therapies by providing better clinical results than other conventional cancer therapies.

Table of Contents

1. Introduction to CD Antigen Based Cancer Therapeutics

  • 1.1. Prologue to CD Antigens
  • 1.2. Background: Discovering CD Antigens in Cancer Therapy
  • 1.3. Historical Aspects of CD Antigen Based Cancer Therapeutics

2. Significance of CD Antigens: Normal Cells versus Cancer Cells

  • 2.1. CD Antigens in Normal Cells
  • 2.2. CD Antigens in Cancer

3. Working Mechanism of CD Antigen Based Cancer Therapeutics

4. Commercial Cancer Therapeutics Based on CD Antigens

  • 4.1. Monoclonal Antibodies
  • 4.2. Antibody Drug Conjugates
  • 4.3. Bispecific Antibodies

5. Recent Commercial Trends in CD Antigen Based Cancer Therapeutics

  • 5.1. CAR-T Cell Therapy
  • 5.2. Aptamers
  • 5.3. Immunoconjugates
    • 5.3.1. Radio Immunoconjugate
    • 5.3.2. Toxin Immunoconjugate
  • 5.4. Novel CD Antigen Based Antibodies
    • 5.4.1. Bispecific T-Cell Engager Antibody (BiTEs)
    • 5.4.2. DART and TandAb

6. Major CD Antigens as Targets for Cancer Therapy

  • 6.1. CD20
  • 6.2. CD19
  • 6.3. CD137
  • 6.4. CD38
  • 6.5. CD70
  • 6.6. CD22
  • 6.7. CD30
  • 6.8. CD33
  • 6.9. CD37

7. Major CD Antigens as Cancer Diagnostic Agents

  • 7.1. CD20
  • 7.2. CD5
  • 7.3. CD56
  • 7.4. CD66e
  • 7.5. CD15
  • 7.6. CD30
  • 7.7. CD3

8. Major CD Antigens in Cancer Research

  • 8.1. CD34
  • 8.2. CD10
  • 8.3. CD26
  • 8.4. CD117
  • 8.5. CD44
  • 8.6. CD57

9. Global CD Antigen Based Therapeutics Market Overview

  • 9.1. Market Progression
  • 9.2. Current Market Scenario
  • 9.3. Global CD Antigen Based Cancer Therapeutics Market Trends
  • 9.4. Global Cancer CD Antigen Inhibitors Pipeline Overview

10. Price & Dosage Analysis of Major CD Antigen Based Cancer Therapies

  • 10.1. Rituximab (CD20)
  • 10.2. Ofatumumab (CD20)
  • 10.3. Obinutuzumab (CD20)
  • 10.4. Daratumumab (CD38)
  • 10.5. Brentuximab Vedotin (CD30)
  • 10.6. Gemtuzumab Ozogamicin (CD33)
  • 10.7. Inotuzumab Ozogamicin (CD22)
  • 10.8. Ibritumomab Tiuxetan (CD20)
  • 10.9. Blinatumomab (CD19, CD3)
  • 10.10. Tisagenlecleucel (CD19)

11. Marketed Cancer CD Antigen Inhibitors Clinical & Patent Insight

  • 11.1. Rituximab (MabThera & Rituxan)
  • 11.2. Obinutuzumab (Gazyva & Gazyvaro)
  • 11.3. Ibritumomab Tiuxetan (Zevalin & Zevamab)
  • 11.4. Rituximab Biosimilar (AcellBia & USMAL)
  • 11.5. Rituximab Biosimilar (Reditux & Tidecron)
  • 11.6. Rituximab Biosimilar (Blitzima, Ritemvia, Truxima & Tuxella)
  • 11.7. Rituximab Biosimilar (Novex)
  • 11.8. Rituximab Biosimilar (RituxiRel, Toritz & Toritz RA)
  • 11.9. Rituximab Biosimilar (Maball)
  • 11.10. Rituximab Biosimilar (Kikuzubam)
  • 11.11. Rituximab Biosimilar (Mabtas)
  • 11.12. Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat & Remniq)
  • 11.13. Avelumab (BAVENCIO)
  • 11.14. Pembrolizumab (Keytruda)
  • 11.15. Atezolizumab (TECENTRIQ)
  • 11.16. Durvalumab (Imfinzi)
  • 11.17. Rituximab Biosimilar (Zytux)

12. Global CD Antigen Cancer Therapy Market Dynamics

  • 12.1. Market Growth Drivers
    • 12.1.1. Large Patient Base
    • 12.1.2. Unmet Medical Need
    • 12.1.3. Better Safety Profile
    • 12.1.4. Accelerated Research & Development: Newly Identified CD Antigens in Cancer
    • 12.1.5. Acquiring Major Share of the Modern Cancer Therapy Market
    • 12.1.6. Strong Clinical Pipeline
  • 12.2. CD Antigen Market Challenges
    • 12.2.1. High Prices of CD Antigen Based Cancer Therapeutics
    • 12.2.2. Difficulties in Differentiating CD Target on Cancer Cells
    • 12.2.3. High Production Cost Due to Complex Structure

13. Global CD Antigens Cancer Therapy Market Future Forecast

14. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 14.1. Research
  • 14.2. Preclinical
  • 14.3. Phase-I

15. Cancer CD3 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 15.1. Preclinical
  • 15.2. Phase-I
  • 15.3. Phase-II

16. Cancer CD4 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 16.1. Phase-I

17. Cancer CD7 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 17.1. Preclinical

18. Cancer CD19 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 18.1. Phase-I
  • 18.2. Phase-I/II
  • 18.3. Phase-II
  • 18.4. Phase-III

19. Cancer CD20 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 19.1. Unknown
  • 19.2. Research
  • 19.3. Preclinical
  • 19.4. Clinical
  • 19.5. Phase-I
  • 19.6. Phase-I/II
  • 19.7. Phase-II
  • 19.8. Phase-III
  • 19.9. Registered

20. Cancer CD22 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 20.1. Preclinical
  • 20.2. Phase-III
  • 20.3. Registered

21. Cancer CD 26 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 21.1. Preclinical
  • 21.2. Phase-I/II

22. Cancer CD27 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 22.1. Research
  • 22.2. Preclinical
  • 22.3. Phase-II

23. Cancer CD30 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 23.1. Phase-I

24. Cancer CD33 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 24.1. Phase-I
  • 24.2. Phase-I/II

25. Cancer CD38 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 25.1. Research
  • 25.2. Preclinical
  • 25.3. Phase-I/II
  • 25.4. Phase-III

26. Cancer CD44 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 26.1. Preclinical
  • 26.2. Phase-I

27. Cancer CD45 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 27.1. Phase-III

28. Cancer CD46 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 28.1. Research

29. Cancer CD 47 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 29.1. Research
  • 29.2. Preclinical
  • 29.3. Phase-I
  • 29.4. Phase-I/II

30. Cancer CD52 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 30.1. Research
  • 30.2. Preclinical

31. Cancer CD55 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 31.1. Preclinical
  • 31.2. Phase-II

32. Cancer CD56 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 32.1. Phase-II

33. Cancer CD66 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 33.1. Phase-I

34. Cancer CD70 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 34.1. Phase-II

35. Cancer CD71 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 35.1. Preclinical

36. Cancer CD98 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 36.1. Phase-I

37. Cancer CD200 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 37.1. Preclinical
  • 37.2. Clinical
  • 37.3. Phase-II

38. Cancer CD223 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 38.1. Preclinical
  • 38.2. Phase-I
  • 38.3. Phase-I/II
  • 38.4. Phase-II

39. Cancer CD248 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 39.1. Preclinical
  • 39.2. Phase-II

40. Cancer CD274 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 40.1. Research
  • 40.2. Preclinical
  • 40.3. Clinical
  • 40.4. Phase-I
  • 40.5. Phase-I/II

41. Cancer CD319 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 41.1. Phase-I

42. Cancer Multiple Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 42.1. Preclinical
  • 42.2. Phase-I
  • 42.3. Phase-I/II

43. Competitive Landscape

  • 43.1. AryoGen Biopharma
  • 43.2. Biocad
  • 43.3. Biogen Idec
  • 43.4. Celltrion
  • 43.5. Genentech
  • 43.6. Genmab
  • 43.7. GLYCART Biotechnology
  • 43.8. Hetero Drugs
  • 43.9. mAbxience
  • 43.10. MedImmune
  • 43.11. Merck
  • 43.12. Sandoz
  • 43.13. UCB

List of Figures

  • Figure 1-1: Evolution of CD Antigen Based Therapeutic Antibodies in Cancer Therapy
  • Figure 2-1: CD Antigens as Markers on Normal Leukocytes
  • Figure 2-2: Significance of CD Antigen in Cancer Cell & its Inhibition by Therapeutic Antibody
  • Figure 4-1: Types of CD Antigen Based Cancer Therapeutics
  • Figure 4-2: Structure of Monoclonal Antibody
  • Figure 4-3: Types of Therapeutic Monoclonal Antibodies
  • Figure 4-4: Architecture of Antibody Drug Conjugates
  • Figure 4-5: Bispecific Antibody Structure
  • Figure 5-1: Advanced CD Antigen Targeting Cancer Therapies
  • Figure 5-2: Structure of Radio Immunoconjugate
  • Figure 5-3: Structure of Bispecific T-Cell Engager Antibody
  • Figure 5-4: Structure of Dual Affinity Re-Targeting Antibody
  • Figure 6-1: Mechanism of Action of Anti-CD20 Monoclonal Antibody Rituximab
  • Figure 6-2: Mechanism of Action of Anti-CD30 Antibody Drug Conjugate Brentuximab Vedotin
  • Figure 9-1: Global - Cancer Therapeutic Monoclonal Antibody Market Share (%), 2017
  • Figure 9-2: Global - CD20 Cancer Therapeutic Segmentation by Region (%), 2017
  • Figure 9-3: Global - Rituximab Sales (US$ Billion), 2013-2016
  • Figure 9-4: Global - Ofatumumab Sales (US$ Million), 2013-2016
  • Figure 9-5: Global - Obinutuzumab Sales (US$ Million), 2015 & 2016
  • Figure 9-6: Global - Ibritumomab Tiuxetan Sales (US$ Million), 2013-2016
  • Figure 9-7: Global - Daratumumab Sales (US$ Million), 2015-2017*
  • Figure 9-8: Global - Daratumumab Half Yearly Sales (US$ Million), 2016 & 2017
  • Figure 9-9: Global - Brentuximab Vedotin Sales (US$ Million), 2014-2017
  • Figure 9-10: Global - Blinatumomab Sales (US$ Million), 2015-2017*
  • Figure 9-11: Global - Blinatumomab Sales (US$ Million), 2015-2017
  • Figure 9-12: Global - Cancer CD Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
  • Figure 9-13: Global - Cancer CD Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-14: Global - Cancer CD3 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-15: Global - Cancer CD3 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-16: Global - Cancer CD19 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-17: Global - Cancer CD19 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-18: Global - Cancer CD20 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-19: Global - Cancer CD20 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-20: Global - Cancer CD22 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-21: Global - Cancer CD22 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-22: Global - Cancer CD26 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-23: Global - Cancer CD26 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-24: Global - Cancer CD27 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-25: Global - Cancer CD27 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-26: Global - Cancer CD33 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-27: Global - Cancer CD33 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-28: Global - Cancer CD38 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-29: Global - Cancer CD38 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-30: Global - Cancer CD44 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-31: Global - Cancer CD44 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-32: Global - Cancer CD47 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-33: Global - Cancer CD47 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-34: Global - Cancer CD52 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-35: Global - Cancer CD52 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-36: Global - Cancer CD55 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-37: Global - Cancer CD55 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-38: Global - Cancer CD200 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-39: Global - Cancer CD200 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-40: Global - Cancer CD223 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-41: Global - Cancer CD223 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-42: Global - Cancer CD248 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-43: Global - Cancer CD248 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-44: Global - Cancer CD274 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
  • Figure 9-45: Global - Cancer CD274 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
  • Figure 9-46: Global - Cancer CD Multiple Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
  • Figure 9-47: Global - Cancer CD Multiple Antigen Inhibitors Pipeline by Phase (Number), 2017
  • Figure 9-48: Global - Cancer CD Total Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
  • Figure 9-49: Global - Cancer CD Total Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
  • Figure 10-1: US - Rituximab Intravenous Solution Price by Concentration (10mg/mL) (US$/Unit), 2017
  • Figure 10-2: US - Rituximab Vial Price by Quantity (US$), 2017
  • Figure 10-3: Rituximab Treatment Cost Analysis by Route of Administration (US$), 2017
  • Figure 10-4: US - Ofatumumab Intravenous Solution Price by Concentration (20mg/mL) (US$/Unit), 2017
  • Figure 10-5: US - Ofatumumab Vial Price by Quantity (US$), 2017
  • Figure 10-6: Ofatumumab - Treatment Dosage Analysis (mg)
  • Figure 10-7: Ofatumumab - Price Analysis by Dosage (US$)
  • Figure 10-8: Obinutuzumab First Cycle Dosage Analysis (mg)
  • Figure 10-9: Obinutuzumab Treatment Dosage Analysis (mg)
  • Figure 10-10: US - Obinituzumab Solution Price (US$), 2017
  • Figure 10-11: Obinutuzumab - Therapy First Cycle Average Cost (US$), 2017
  • Figure 10-12: Obinutuzumab Average Treatment Cost (US$), 2017
  • Figure 10-13: Daratumumab Monotherapy Dosage Analysis (mg)
  • Figure 10-14: Daratumumab Combination Therapy Dosage Analysis (mg)
  • Figure 10-15: US - Daratumumab Intravenous Solution Cost by Concentration (20mg/mL) (US$/Unit), 2017
  • Figure 10-16: Daratumumab Vial Price Analysis by Quantity (US$), 2017
  • Figure 10-17: Daratumumab Monotherapy Average Cost Analysis (US$), 2017
  • Figure 10-18: Daratumumab Combination Therapy Average Cost Analysis (US$), 2017
  • Figure 10-19: US - Brentuximab Vedotin Price Analysis, (US$), 2017
  • Figure 10-20: US - Brentuximab Vedotin Treatment Expenditure (US$), 2014
  • Figure 10-21: US - Brentuximab Vedotin Treatment Cost (US$), 2017
  • Figure 10-22: Global - Gemtuzumab Ozogamicin Treatment Cycle Price Analysis (US$), 2010 & 2017
  • Figure 10-23: US - Ibritumomab Tiuxetan Product & Dose Price Analysis (US$), 2017
  • Figure 10-24: US - Blinatumomab Dosage Average Price Analysis (US$), 2017
  • Figure 10-25: US - Blinatumomab Treatment First Cycle Average Cost (US$), 2017
  • Figure 10-26: US - Blinatumomab Treatment Subsequent Cycle Average Cost (US$), 2017
  • Figure 12-1: Global CD Antigen Based Cancer Therapy Market Driving Factors
  • Figure 12-2: Gemtuzumab vs Best Available Therapy Survival Rate
  • Figure 12-3: Global CD Antigen Based Cancer Therapeutic Market Challenges

List of Tables

  • Table 10-1: Rituximab Dosage Indications for Treatment of Different Cancer Conditions